PolyPid Stock

PolyPid EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of PolyPid (PYPD) as of Sep 5, 2026 is -147.79 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -111.14 % — a change of 32.98% (lower).

EBIT/Assets

-147.79 %

YoY

32.98%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of PolyPid is 2026 -147.79 % . Operating Income to Assets Ratio (EBIT/Assets) of PolyPid was 2025 -111.14 % . It decreases by 32.98% lower compared to the previous year.

The PolyPid EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-126.79 USD
Jan 1, 2019
-54.97 USD
Jan 1, 2020
-34.64 USD
Jan 1, 2021
-96.93 USD
Jan 1, 2022
-149.74 USD
Jan 1, 2023
-148.21 USD
Jan 1, 2024
-111.14 USD
Jan 1, 2025
-147.79 USD
The PolyPid EBIT/Assets history
YEAREBIT/AssetsYoY
-147.79 %+32.98%
-111.14 %-25.01%
-148.21 %-1.02%
-149.74 %+54.49%
-96.93 %+179.82%
-34.64 %-36.99%
-54.97 %-56.65%
-126.79 %+111.17%
-60.04 %+12.59%
-53.33 %-88.27%
-454.68 %
Access this data via the Eulerpool API

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PolyPid stock

Operating Income to Assets Ratio (EBIT/Assets) of PolyPid is -147.79 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of PolyPid changed from -111.14 % to -147.79 %, representing a 32.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) PolyPid since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s PolyPid with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — PolyPid

All Key Metrics — PolyPid